Literature DB >> 23333000

Prevalence of ST131 among fluoroquinolone-resistant Escherichia coli obtained from rectal swabs before transrectal prostate biopsy.

Michael A Liss1, Ellena M Peterson, Brian Johnston, Kathryn Osann, James R Johnson.   

Abstract

OBJECTIVE: To identify the prevalence and characteristics of fluoroquinolone-resistant (FQ-R) Escherichia coli ST131 isolates in men undergoing ultrasound-guided transrectal prostate biopsy (TPB).
MATERIALS AND METHODS: Twenty-seven FQ-R E coli isolates from rectal swabs from 136 men undergoing TPB at 3 institutions in southern California (January 2009 to March 2010), with a focus on repeat biopsy patients, were assessed for E coli phylogenetic group, sequence type ST131 status, extended virulence genotype, pulsed-field gel electrophoresis profile, and antimicrobial susceptibility profile.
RESULTS: ST131 accounted for 70% of the 27 FQ-R pre-TPB E coli rectal isolates, including 82% of those from non-Asians vs 20% from Asians (P = .017). ST131 was associated negatively with prebiopsy enemas and positively with previous TPB. Compared with non-ST131 isolates, the ST131 isolates had a significantly higher prevalence of 4 virulence genes (sat, usp, ompT, and malX), distinctive virulence profiles, and numerically higher virulence scores (median, 12 vs 8), but similar antimicrobial resistance scores. Most rectal ST131 isolates exhibited pulsed-field gel electrophoresis profiles typical of clinical ST131 isolates.
CONCLUSION: In our locale, the epidemic multidrug-resistant ST131 clonal group accounts for 70% of FQ-R rectal E coli isolates among men undergoing TPB. Such ST131 isolates have distinctive virulence profiles, are extensively antimicrobial-resistant, and are negatively associated with Asian race. Further investigation is needed regarding risk factors for and clinical consequences of colonization with such strains among men undergoing TPB.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23333000      PMCID: PMC4066977          DOI: 10.1016/j.urology.2012.10.056

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  29 in total

1.  Infection: prostate biopsy-infection and prior fluoroquinolone exposure.

Authors:  Michael A Liss
Journal:  Nat Rev Urol       Date:  2011-10-11       Impact factor: 14.432

2.  Complications after prostate biopsy: data from SEER-Medicare.

Authors:  Stacy Loeb; H Ballentine Carter; Sonja I Berndt; Winnie Ricker; Edward M Schaeffer
Journal:  J Urol       Date:  2011-09-23       Impact factor: 7.450

3.  Infectious complications and hospital admissions after prostate biopsy in a European randomized trial.

Authors:  Stacy Loeb; Suzanne van den Heuvel; Xiaoye Zhu; Chris H Bangma; Fritz H Schröder; Monique J Roobol
Journal:  Eur Urol       Date:  2012-01-05       Impact factor: 20.096

4.  Infection after transrectal ultrasonography-guided prostate biopsy: increased relative risks after recent international travel or antibiotic use.

Authors:  Uday Patel; Prokar Dasgupta; Peter Amoroso; Ben Challacombe; James Pilcher; Roger Kirby
Journal:  BJU Int       Date:  2011-10-31       Impact factor: 5.588

Review 5.  Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study.

Authors:  B Djavan; M Waldert; A Zlotta; P Dobronski; C Seitz; M Remzi; A Borkowski; C Schulman; M Marberger
Journal:  J Urol       Date:  2001-09       Impact factor: 7.450

6.  Prevalence of fluoroquinolone-resistant Escherichia coli before and incidence of acute bacterial prostatitis after prostate biopsy.

Authors:  Satoru Minamida; Takefumi Satoh; Kenichi Tabata; Masaki Kimura; Hideyasu Tsumura; Shinji Kurosaka; Kazumasa Matsumoto; Tetsuo Fujita; Masatsugu Iwamura; Shiro Baba
Journal:  Urology       Date:  2011-09-10       Impact factor: 2.649

7.  Escherichia coli bloodstream infection after transrectal ultrasound-guided prostate biopsy: implications of fluoroquinolone-resistant sequence type 131 as a major causative pathogen.

Authors:  Deborah A Williamson; Sally A Roberts; David L Paterson; Hanna Sidjabat; Anna Silvey; Jonathan Masters; Michael Rice; Joshua T Freeman
Journal:  Clin Infect Dis       Date:  2012-03-14       Impact factor: 9.079

8.  Virulence characteristics and phylogenetic background of multidrug-resistant and antimicrobial-susceptible clinical isolates of Escherichia coli from across the United States, 2000-2001.

Authors:  James R Johnson; Michael A Kuskowski; Abby Gajewski; Daniel F Sahm; James A Karlowsky
Journal:  J Infect Dis       Date:  2004-10-07       Impact factor: 5.226

9.  Molecular epidemiological analysis of Escherichia coli sequence type ST131 (O25:H4) and blaCTX-M-15 among extended-spectrum-β-lactamase-producing E. coli from the United States, 2000 to 2009.

Authors:  James R Johnson; Carl Urban; Scott J Weissman; James H Jorgensen; James S Lewis; Glen Hansen; Paul H Edelstein; Ari Robicsek; Timothy Cleary; Javier Adachi; David Paterson; John Quinn; Nancy D Hanson; Brian D Johnston; Connie Clabots; Michael A Kuskowski
Journal:  Antimicrob Agents Chemother       Date:  2012-02-21       Impact factor: 5.191

10.  Insights into a multidrug resistant Escherichia coli pathogen of the globally disseminated ST131 lineage: genome analysis and virulence mechanisms.

Authors:  Makrina Totsika; Scott A Beatson; Sohinee Sarkar; Minh-Duy Phan; Nicola K Petty; Nathan Bachmann; Marek Szubert; Hanna E Sidjabat; David L Paterson; Mathew Upton; Mark A Schembri
Journal:  PLoS One       Date:  2011-10-28       Impact factor: 3.240

View more
  8 in total

1.  Rapid Identification of Rectal Multidrug-resistant Escherichia coli Before Transrectal Prostate Biopsy.

Authors:  Veronika L Tchesnokova; Linda L Ottley; Kyoko Sakamoto; Joshua Fierer; Evgeni Sokurenko; Michael A Liss
Journal:  Urology       Date:  2015-08-20       Impact factor: 2.649

Review 2.  A new clone sweeps clean: the enigmatic emergence of Escherichia coli sequence type 131.

Authors:  Ritu Banerjee; James R Johnson
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

3.  Incidence of infectious complications following transrectal ultrasound-guided prostate biopsy in Calgary, Alberta, Canada: A retrospective population-based analysis.

Authors:  Jan Krzysztof Rudzinski; Jun Kawakami
Journal:  Can Urol Assoc J       Date:  2014-05       Impact factor: 1.862

4.  Long-Term Care Facilities Are Reservoirs for Antimicrobial-Resistant Sequence Type 131 Escherichia coli.

Authors:  Mary J Burgess; James R Johnson; Stephen B Porter; Brian Johnston; Connie Clabots; Brian D Lahr; James R Uhl; Ritu Banerjee
Journal:  Open Forum Infect Dis       Date:  2015-02-17       Impact factor: 3.835

Review 5.  Epidemic potential of Escherichia coli ST131 and Klebsiella pneumoniae ST258: a systematic review and meta-analysis.

Authors:  M J D Dautzenberg; M R Haverkate; M J M Bonten; M C J Bootsma
Journal:  BMJ Open       Date:  2016-03-17       Impact factor: 2.692

6.  Multiple Modes of Action of a Monoclonal Antibody against Multidrug-Resistant Escherichia coli Sequence Type 131-H30.

Authors:  Luis M Guachalla; Katharina Hartl; Cecília Varga; Lukas Stulik; Irina Mirkina; Stefan Malafa; Eszter Nagy; Gábor Nagy; Valéria Szijártó
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

7.  Prevalence of Plasmid-Mediated Quinolone Resistance (PMQRs) Determinants and Whole Genome Sequence Screening of PMQR-Producing E. coli Isolated from Men Undergoing a Transrectal Prostate Biopsy.

Authors:  Katarzyna Piekarska; Katarzyna Zacharczuk; Tomasz Wołkowicz; Rafał Gierczyński
Journal:  Int J Mol Sci       Date:  2022-08-10       Impact factor: 6.208

8.  Editorial commentary: flying under the radar: the stealth pandemic of Escherichia coli sequence type 131.

Authors:  Ebbing Lautenbach
Journal:  Clin Infect Dis       Date:  2013-08-06       Impact factor: 9.079

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.